## APPENDIX A

Roche Proposed Exhibit Number	Document Identification/Bates- Label	<b>Document Description</b>	Exhibit to Roche's Opposition To Amgen's Motion For Summary Judgment On the Antitrust And State Law Counterclaims
Roche Preliminary Deposition Designations List	Sharer Ex. 11	Amgen at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Transcript	Exhibit 1
Roche Preliminary Deposition Designations	March 9, 2007 excerpts of deposition transcript of Maureen Michael	7:1-8, 10:10-17, 13:6-18, 14:14- 15:15, 31:20-32:5, 36:8-15, 36:16- 22, 45:1-23, 47:12-20, 55:9-15, 81:15-18	Exhibit 3
Roche Preliminary Deposition Designations List	March 20, 2007 excerpts of deposition transcript of Helen Torley	13:1-4, 121:4-16; 123:13-124:7, 124:8-132:4, 234:2-16, 234:11-16, 379:2-21, 379:22-380:5, 387:4-387:13	Exhibit 4
Roche Proposed Exhibit 5795	R10-004974841- R10-004975230	Mircera WAC Pricing and Contracting Strategies Review Meeting	Exhibit 9
Roche Proposed Exhibit 6110	AM44 0087234- AM44 0087267	PEG-EPO War Game Debrief, Global Marketing/Competitive Intelligence	Exhibit 13
Roche Proposed Exhibit 3908	AM44 0715533- AM44 0715534	Email from Torley to Azelby re Jim Follow-up	Exhibit 17
Roche Proposed Exhibit 3603	AM44 1440662- AM44 1440694	Discounts to Create Cost Recovery Advantage	Exhibit 18
Roche Proposed Exhibit 2278	AM44 0216383- AM44 0216441	2007 - 2009 Epogen Plan Strategic Direction	Exhibit 19
Roche Proposed Exhibit 4034	AM44 1951328- AM44 1951333	Epogen/Aranesp Non Onc 2007-09 Revenue Plan Update	Exhibit 24
Roche Proposed Exhibit 3347	AM44 0007126- AM44 0007166	CRB Presentation	Exhibit 26

Roche Proposed Exhibit 6534	AM44 0664015- AM44 0664020	Memo from Bleil to Torley re Recap of Strategic Planning Session	Exhibit 54
Roche Proposed Exhibit 3583	AM44 0392145- AM44 0392211	Developing a Broader and Bolder Partnership with	Exhibit 57
Roche Preliminary Deposition Designations List	March 27, 2007 excerpt of deposition transcript of Kevin Sharer	76:19-79:6, 79:21-80:4, 82:5-22,	Exhibit 61
Roche Proposed Exhibit 3884	AM44 1027895- AM44 1027896	Email from Rath to Morrow and Torley re Summary of Discussion with Fresenius	Exhibit 63
Roche Preliminary Deposition Designations List	April 2, 2007 excerpt of deposition transcript of Leslie Mirani	9:13-79, 30:9-31:8, 157:22-158:2, 164:16-:19	Exhibit 67
Roche Proposed Exhibit 5900	AM44 0231755- AM44 0231777	NACO Operating Review Storyboard	Exhibit 68
Roche Preliminary Deposition Designations List	March 27, 2007 excerpt of deposition transcript of Tracey Mooney	17:10-13, 17:24-18:2, 18:20-19:7, 19:18-20:16, 21:4-22:14, 21:15-22, 23:3-24:3, 43:7-12,	Exhibit 72
Roche Preliminary Deposition Designations List	April 2, 2007 excerpt of deposition transcript of Dennis Kogod	61:5-11	Exhibit 73
Roche Proposed Exhibit 6417	AM44 0188476- AM44 0188516	Qualitative Research - Product X in CKD	Exhibit 75
Roche Proposed Exhibit 7026	FMCNA 000001- FMCNA 000047	Sourcing & Supply Agreement No. 200600447 by Amgen, Inc. and Fresenius Medical Care Holdings, Inc.	Exhibit 76
Roche Proposed Exhibit 2457	AM44 0095167- AM44 0095175	Amgen Achievement Agreement (AAA) Contract	Exhibit 100

AM44 0019536- AM44 0019596	S2 Hospital Contract Training, July 2004	Exhibit 101
AM44 0095176- AM44 0095180	Amgen Disproportionate Share Hospital (DSh) Program	Exhibit 102
AM44 0123862	Aranesp Freedom of Less Frequent Dosing	Exhibit 103
AM44 0393892- AM44 0393909	Contracted Hospital Q1 2006 Metric Report	Exhibit 104
AM44 1532833- AM44 1532857	Hospital Purchasing Agreement by and Between Amgen and City of Hope National Medical Center	Exhibit 106
AM44 0192555- AM44 0192573	US Nephrology Business Unit Competitive Response Plan	Exhibit 111
AM44 0192047- AM44 0192078	SLOT War Game Follow Up - Commercial Analytics	Exhibit 129
AM44 0230289- AM44 0230328	Aranesp Strategic Direction and Key Initiatives	Exhibit 142
R000231067- R000231073	CERA Dialysis Launch Strategy/POA Outline	Exhibit 157
AM44 0231710- AM44 0231732	NACO Operating Review Storyboard	Exhibit 169
March 22, 2007 excerpts of deposition transcript of Anthony Messana	15:24-16:11, 22:15-25, 25:15-18, 30:18-31:3, 33:21-34:9, 34:3-16, 35:2-11, 41:22-43:6	Exhibit 178
AM44 0009433- AM44 0009452	NBU Update	Exhibit 193
AM44 1948561- AM44 1948563	DaVita Draft Term Sheet	Exhibit 209
AM44 0145693- AM44 0145754	EPOGEN/ARANESP Dialysis 2004-2006 US Brand Plan	Exhibit 216
	AM44 0019596  AM44 0095176- AM44 0095180  AM44 0123862  AM44 0393892- AM44 0393909  AM44 1532833- AM44 1532857  AM44 0192573  AM44 0192047- AM44 0192078  AM44 0230289- AM44 0230328  R000231067- R000231073  AM44 0231710- AM44 0231732  March 22, 2007 excerpts of deposition transcript of Anthony Messana  AM44 0009433- AM44 0009452  AM44 1948561- AM44 1948563  AM44 0145693-	AM44 0019596         2004           AM44 0095176- AM44 0095180         Amgen Disproportionate Share Hospital (DSh) Program           AM44 0123862         Aranesp Freedom of Less Frequent Dosing           AM44 0393892- AM44 0393909         Contracted Hospital Q1 2006 Metric Report           AM44 1532833- AM44 1532857         Hospital Purchasing Agreement by and Between Amgen and City of Hope National Medical Center           AM44 0192555- AM44 0192573         US Nephrology Business Unit Competitive Response Plan           AM44 0192047- AM44 0192078         SLOT War Game Follow Up - Commercial Analytics           AM44 0230289- AM44 0230289- AM44 0230328         Aranesp Strategic Direction and Key Initiatives           R000231067- R000231073         CERA Dialysis Launch Strategy/POA Outline           AM44 0231710- AM44 0231732         NACO Operating Review Storyboard           March 22, 2007 excerpts of deposition transcript of Anthony Messana         15:24-16:11, 22:15-25, 25:15-18, 30:18-31:3, 33:21-34:9, 34:3-16, 35:2-11, 41:22-43:6           AM44 0009433- AM44 0009452         NBU Update           AM44 1948561- AM44 1948563         DaVita Draft Term Sheet